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Adult-type granulosa cell tumors (AGCTs) are sex-cord derived neoplasms with a propensity for late relapse. Hormonal modulators have been used empirically in the treatment of recurrent AGCT, albeit with
limited success. To provide a more rigorous foundation for hormonal therapy in AGCT, we used a multimodal approach to characterize the expressions of key hormone biomarkers in 175 tumor specimens and
51 serum samples using RNA sequencing, immunohistochemistry, RNA in situ hybridization, quantitative
PCR, and circulating biomarker analysis, and correlated these results with clinical data. We show that
FSH receptor and estrogen receptor beta (ERβ) are highly expressed in the majority of AGCTs, whereas
the expressions of estrogen receptor alpha (ERα) and G-protein coupled estrogen receptor 1 are less prominent. ERβ protein expression is further increased in recurrent tumors. Aromatase expression levels show
high variability between tumors. None of the markers examined served as prognostic biomarkers for
progression-free or overall survival. In functional experiments, we assessed the effects of FSH, estradiol
(E2), and the aromatase inhibitor letrozole on AGCT cell viability using 2 in vitro models: KGN cells and
primary cultures of AGCT cells. FSH increased cell viability in a subset of primary AGCT cells, whereas
E2 had no effect on cell viability at physiological concentrations. Letrozole suppressed E2 production in
AGCTs; however, it did not impact cell viability. We did not find preclinical evidence to support the clinical
use of aromatase inhibitors in AGCT treatment, and thus randomized, prospective clinical studies are
needed to clarify the role of hormonal treatments in AGCTs.
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Adult-type granulosa cell tumors (AGCTs) are sex cord stromal tumors representing 3% to
5% of ovarian malignancies. A defining feature of AGCTs is a somatic mutation (c0.402C > G;
p.C134W) in the FOXL2 gene, which is thought to play a pivotal role in oncogenesis [1].
These tumors are characterized by slow growth and a generally favorable prognosis, with
Abbreviations: AGCT, adult-type granulosa cell tumor; E2, estradiol; ER, estrogen receptor; FSHR, FSH receptor; GPER,
G-protein linked estrogen receptor; hGL, human granulosa-luteal; IHC, immunohistochemistry; qPCR, quantitative PCR; RNASeq, RNA sequencing; TMA, tumor tissue microarray
Received 10 October 2019
Accepted 11 March 2020
First Published Online 16 March 2020
Corrected and Typeset 13 April 2020

April 2020 | Vol. 4, Iss. 4
doi: 10.1210/jendso/bvaa034 | Journal of the Endocrine Society | 1–20

Downloaded from https://academic.oup.com/jes/article/4/4/bvaa034/5807493 by Washington University in St. Louis user on 16 November 2020

Ulla-Maija Haltia,1,2,3 Marjut Pihlajoki,2 Noora Andersson,2 Lotta Mäkinen,2
Johanna Tapper,1 Alejandra Cervera,3 Hugo M. Horlings,4 Ursula Turpeinen,5
Mikko Anttonen,5 Ralf Bützow,6 Leila Unkila-Kallio,1 Olli Carpén,3,6 David B. Wilson,7,8
Markku Heikinheimo,2,7 and Anniina Färkkilä1,3

2 | Journal of the Endocrine Society | doi: 10.1210/jendso/bvaa034

1. Materials and Methods
A. Patients and Samples
Patient and sample data are shown in Tables 1 and 2. All of the AGCTs tested positive
for the FOXL2 (c0.402C > G; p.C134W) mutation, and histological diagnoses were verified
by an expert pathologist (R.B.). We performed RNA sequencing of freshly frozen tissue
from 6 primary and 4 recurrent tumors. We constructed a tumor tissue microarray (TMA)
containing quadruple cores from 121 primary and 54 recurrent AGCTs from representative
formalin-fixed, paraffin embedded samples (Table 1). Nine tumor samples were available
both as freshly frozen tissue and formalin-fixed, paraffin embedded. For controls, normal
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a 10-year survival of 84% [2]. Up to 30% of patients diagnosed with AGCT experience a
late relapse. The mainstay of treatment for AGCT is surgical resection, but improved medical therapies are needed for advanced and relapsed disease. Current chemotherapeutic
regimens show limited efficacy [3], and no prospectively validated targeted therapies exist
for this unique tumor type.
AGCTs secrete estradiol (E2), inhibin B, and anti-Müllerian hormone, and tumor hormone production accounts for many of the signs and symptoms of the disease [4–6]. AGCTs
are known to express certain hormone receptors [7–9], but the importance of hormonal
signaling in AGCT progression remains uncertain. Hormonal therapies, such as GnRHanalogues and aromatase inhibitors, have been used empirically in AGCT with limited efficacy [10, 11]; however, the biological foundation for these treatments has not been clearly
established.
Clinically, AGCTs are often diagnosed at perimenopause when gonadotropin levels rapidly increase, and FSH signaling has been proposed to be 1 of the main drivers of AGCT
growth [12]. In normal granulosa cells, FSH promotes cell proliferation by cAMP-mediated
signaling cascades, leading to increased aromatase (CYP19A1) expression and elevated
serum E2 levels, essential for normal ovarian function [13, 14]. The gene expression profile
of AGCTs has been shown to mimic that of FSH-stimulated granulosa cells [15], suggesting
that this gonadotropin signaling pathway is active in these neoplasms. Regarding CYP19A1,
FSH is known to increase its mRNA levels via specific transcription factors, and FOXL2 has
been shown to act as a direct regulator of this gene [16]. Data concerning the expression and
functionality of CYP19A1 in AGCTs are scarce, although the ability of AGCTs to secrete E2
implies its increased activity in tumor tissue.
Estrogens are known to exert strong mitogenic effects in breast and endometrial cancers
[17, 18] and to inhibit apoptosis in normal granulosa cells [19], but their impact on AGCT proliferation is less clear. The effects of E2 are mediated through two distinct nuclear receptors
estrogen receptor-α (ERα) and -β (ERβ), both expressed in AGCTs [20, 21]. Additionally, E2
can act through a membrane-bound G-protein linked estrogen receptor (GPER1) that has
been observed in AGCTs [22]. The expression levels, prognostic implications, and functional
roles of FSH, CYP19A1, and E2 in AGCTs have not been reported.
Here, using a multimodal approach that combines next-generation sequencing, quantitative real-time PCR (qPCR), RNA in situ hybridization, and immunohistochemistry
(IHC), we profile the expression of the FSH receptor (FSHR), estrogen receptors (ERα,
ERβ, GPER1), and CYP19A1 in a large cohort of FOXL2 mutation-positive AGCTs with
rich clinical and follow-up data. We augment this expression profiling with measurements
of hormone levels in 51 preoperative serum samples. In functional analyses, we show that
FSH increases CYP19A1 expression and E2 production in an established AGCT cell line
(KGN) and in primary cultures of AGCT cells. We demonstrate that stimulation with FSH
increased cell viability in a subset of primary AGCT cells, whereas E2 had a similar effect
only at high concentrations. Our results thus indicate a specific pattern of hormonal dependency in AGCTs and support the further clinical exploration of hormonal modulators in
the treatment of AGCT.
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Table 1. Clinicopathologic Data of the (A) Patients and (B) Samples in the Tumor Tissue
Microarray (TMA)
A Patients n = 138

53 (26–81)
126 (91)
8 (6)
1 (1)
3 (2)
15.0 (0.7–42.3)
51 (37)
87 (63)
91 (66)
24 (17)
23 (17)
n (% of total)
121 (69)
54 (31)
72 (41)
98 (56)
5 (3)
103 (59)
70 (40)
2 (1)
50 (29)
121 (69)
4 (2)
48 (27)
123 (70)
4 (2)
50 (29)
124 (71)
1 (0.5)

a
Median (range)
MP = menopause; n/a = not available.

ovaries (n = 4) were obtained from women undergoing ovariectomy for benign indications.
Serum samples from 47 AGCT patients were collected before surgery for either primary or
recurrent AGCT (Table 2). Short-term primary tumor cell cultures were established from
fresh AGCT samples from 6 patients (Table 3). Three samples of pooled human granulosaluteal (hGL) cells were obtained from women undergoing in vitro fertilization treatment
at the Department of Obstetrics and Gynecology, Helsinki University Hospital. Informed
consent was obtained from patients who donated blood or fresh AGCT tumor samples for
the study. The ethics committee of Helsinki University Central Hospital and the National
Supervisory Authority for Welfare and Health in Finland approved this study.
B. Serum Analyses
Preoperative samples were obtained from 47 AGCT patients (Table 2) within a month before
surgery and prepared and stored at -80°C until the analysis. All the studied serum markers
(FSH, E2, and inhibin B) were measured in the HUSLAB hospital clinical laboratory:
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Age at diagnosis, yearsa
Tumor stage at diagnosis
I
II
III
n/a
Follow-up time, yearsa
Recurrence
Yes
No
Survival
Alive
Dead of AGCT
Dead of other
B Tumor characteristics n = 175
Primary
Recurrent
Microscopic pattern
Better-differentiated
Less-differentiated
n/a
Tumor size
<10 cm
≥10 cm
n/a
Nuclear atypia
High
Low
n/a
Mitotic index
High
Low
n/a
MP status at sample retrieval
Premenopausal
Postmenopausal
n/a

n (% of Total)
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Table 2. Clinicopathologic Data of the (A) Patients and (B) Samples in the Serum Analysis
A Patients n = 47

56 (26–80)
47 (100)
5.3 (0.4–20.9)
19 (40)
24 (51)
4 (9)
n (%)
31 (61)
20 (39)
24 (47)
15 (29)
12 (24)
10 (20)
41 (80)

a
Median (range)
MP = menopause; n/a = not available.

automated immunoassays for FSH [23] and E2 [24] and ELISA for inhibin B [25]. All the
samples were classified as follows according to the patient’s menopausal status at sample
retrieval: “premenopausal” if the patient had 1 or 2 ovaries and menopause was not indicated in the medical records and “postmenopausal” if both ovaries had been removed, independent of age, or if the patient was postmenopausal according to her medical history.
C. RNA Sequencing
Freshly frozen AGCT tissue samples (n = 10) were lysed in RP1 lysis buffer and homogenized
using a Precellys Lysing Kit and tissue homogenizer (Bertin Technologies, France). Total
RNA was extracted from tumor samples according to the manufacturer’s instructions and
further purified with RNA purification kit (Nucleospin RNA/protein kit and RNA Clean
up kit, Macherey-Nagel, Düren, Germany). RNA integrity was verified using Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Poly (A)-containing mRNA molecules were purified from total RNA and fragmented
into approximately 140- to 160-bp pieces using a standard fragmentation reagent. cDNA
was generated using a first-strand using random hexamer-primed reverse transcription,
followed by a second-strand cDNA synthesis and cDNA purification using a standard
purification kit. The synthesized cDNA was subjected to end repair by adding an “A,”
followed by the 3′ end adenylation. cDNA fragments were amplified using standard
PCR and the products were purified. Libraries were quantified and qualified using
Bioanalyzer 2100 (Agilent Technologies, CA, USA) and the ABI StepOnePlus Real-Time
PCR System (Applied Biosystems, CA, USA). The libraries were paired-end sequenced
(read length 100 bp) in a single lane using the Illumina HiSeq X ten system (Illumina,
Inc, CA, USA). Library construction and sequencing were both performed in BGI Tech
Solutions (Hong Kong).
The RNA-Sequencing (RNA-Seq) reads were processed and analyzed with SePIA [26]
on the Anduril framework [27]. After trimming, reads shorter than 20 bp were discarded.
Reads were quantified with Kallisto (v0.44.0) [28] using GENECODE (v25, GRCh38) [29]
followed by tximport (v1.6.0) [30]. Limma (v3.38.3) [31] was used for batch correction and
edgeR (v3.24.3) [32] for differential expression analysis. In differential expression analysis,
false discovery rate < 0.25 was used as a threshold for statistical significance.
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Age at diagnosis, yearsa
Tumor stage at diagnosis
I
Follow-up time, yearsa
Recurrence
Yes
No
n/a
B Samples n = 51
Primary
Recurrent
Tumor size
<10 cm
≥10 cm
n/a
MP status at sample retrieval
Premenopausal
Postmenopausal

n (%)

doi: 10.1210/jendso/bvaa034 | Journal of the Endocrine Society | 5

Table 3. Data on Primary Cultured AGCT Samples
Age of the Patient at
Sample Retrieval and
Menopause Status
(Age at Primary
Diagnosis)

1

Primary

11

53, postMP

2

Recurrent

4

49, postMP (45)

3

Primary

6,5

4

Recurrent

5

68, postMP (59)

5

Primary

4

49, postMP

6

Recurrent

2,5

48, postMP

41, postMP (40)

Proportional
Change in Cell Proportional
Preoperative Number After Change in Cell
Serum HorE2 StimulaNumber After
mone Levels
tion
FSH Stimulation
E2 0.15
InhB 625
FSH 0.1
E2 0.17
InhB 278
FSH 10.1
E2 0.55
InhB > 1000
FSH 41
E2 0.17
InhB 61
FSH 42
E2 0.13
InhB 223
FSH 15.4
E2 0.14
InhB 221
FSH 44.3

0.79

0.87

1.57

1.05

1.40

1.28

1.23

1.43

1.25

1.26

1.03

0.84

MP = menopause

D. Immunostaining
The AGCT TMA and normal ovary tissue sections were subjected to IHC as described [33].
Staining was performed using mouse monoclonal antibody for CYP19A1 [34], rabbit monoclonal antibody for ERα [35], and mouse monoclonal antibody for ERβ [36]. Samples were
scored by 2 independent researchers (U-M.H. and N.A.) and disagreements were resolved
by a joint review. Staining intensity was classified from 0 to 3 (0 = negative, 1 = weak,
2 = moderate, 3 = strong intensity). Images were generated using 3DHISTECH Panoramic
250 FLASH II digital slide scanner at Genome Biology Unit (Research Programs Unit,
Faculty of Medicine, University of Helsinki, and Biocenter Finland). The scanning was done
using 40× objective (Zeiss Plan-Apochromat 40x/NA 0.95) and applying the extended focus
option using 7 focus layers.
E. RNA In Situ Hybridization
RNA in situ hybridization was performed on freshly cut 5-μm sections of the TMA using
RNAscope 2.5 HD detection kit-BROWN (#322310, ACDBio, Milano, IT) for target mRNA
detection. In short, tissue sections were baked for 1 hour at 60°C, then deparaffinized and
treated with hydrogen peroxide for 10 minutes at room temperature. Target retrieval was
performed for 15 minutes at 100°C, followed by protease plus treatment for 15 minutes at
40°C. The probes Hs-FSHR (#400501), Hs-CYP19A1 (#430861), Hs-GPER (#553361), positive control probe Hs-PPIB (#313901), and negative control probe DapB (#310043) were
hybridized for 2 hours at 40°C followed by signal amplification steps. The samples were
incubated for 60 minutes with AMP 5–reagent. The sections were next treated with DAB for
10 minutes at room temperature followed by counterstaining with 50% hematoxylin. The
sections were dipped in ammonium water and dehydrated in ethanol series and UltraClear
before mounting. Two researchers (U-M.H. and N.A.) performed the scoring independently
and disagreements were resolved by a joint review. Staining intensity was classified from 0
to 3 (0 = negative, 1 = weak, 2 = moderate, 3 = high intensity).
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Sample
ID

Primary
or
Tumor
Recurrent
Size
Tumor
(in cm)
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F. Hormone Stimulation in KGN Cell Line and Primary Cultured AGCT Cells

G. qPCR
Total RNA was extracted using the NucleoSpin RNA/Protein kit (Macherey-Nagel, Düren,
DE). Reverse transcription was performed using the Reverse Transcriptase Core Kit, and
qPCR was carried out using the MESA GREEN qPCR MasterMix Plus for SYBR Assay (both
from Eurogentec, Seraing, BE). ACTB was used as reference gene for mRNA expression.
H. E2 Measurement
Medium was collected from KGN and AGCT primary cells at 96-hour time point and
analyzed for E2 concentration using a mass spectrophotometer at HUSLAB. Calibrators
containing 25 to 1000 pmol/L of estradiol (Cerilliant) were prepared in 50% methanol. Forty
microliters of sample extracts and calibrators were analyzed on a liquid chromatography
tandem mass spectometry system equipped with an AB Sciex 5500 triple quadrupole mass
spectrometer. Data were acquired and processed with the Analyst Software (Ver 1.6.2; AB
Sciex).
I. Statistical Analyses
The immunohistochemical data and categorical variables were analyzed with contingency
tabling (2 × 2) and chi-square or Fisher exact tests. For cell culture data, 1-way ANOVA
followed by Mann-Whitney U-test, with-control Dunnett or Student t-test was used. The
comparison between primary and recurrent tumors was performed by matched-pair t-test
analysis. Serum hormone levels differed from normal distribution even after performing
logarithmic transformation and thus Spearman´s rho was reported. Survival curves of different groups were illustrated by Kaplan-Meier plots and compared with the log-rank test.
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The FOXL2 c0.402C > G mutation-positive KGN cell line [37], originating from a recurrent AGCT, was obtained from the Riken BioResource Center. KGN cells were
passaged < 6 months following receipt or resuscitation of a frozen cell vial, and tested negative for mycoplasma infection. The cells were tested positive for the FOXL2 (c0.402C > G;
p.C134W) mutation. Short-term primary tumor cell cultures were established as described
[38] from fresh primary (n = 3) or recurrent (n = 3) AGCT samples, all tested positive for the
FOXL2 (c0.402C > G; p.C134W) mutation. To increase the cell number, primary AGCT cells
were first cultured for 3 to 4 days in DMEM/Ham’s F-12 medium, supplemented with 10%
fetal calf serum, penicillin/streptomycin, and L-glutamine in a humidified environment at
37°C and 5% CO. hGL cells were obtained from women undergoing in vitro fertilization.
Each of the 3 hGL pools consisted of granulosa-luteal cells derived from 78 to 122 mature
ovulatory follicles from 4 to 7 different patients. The hGL cells were isolated as previously
described [39], followed by suspension in DMEM/F12 growth medium, supplemented with
2.5% Nu-serum I, ITS+ TM Premix (both from BD Biosciences, Bedford, MA, USA), penicillin/
streptomycin, and L-glutamine (Gibco).
Both KGN and primary cultured AGCT cells were grown for 10 or 3 days before hormone
stimulation, respectively, in phenol red free DMEM:F12 medium supplemented with 10%
charcoal stripped fetal calf serum, L-glutamine, and antibiotics to deplete the cells from
external hormones. Next, 10 000 KGN and primary AGCT cells per well were plated on
96-well plates in hormone-depleted medium for the cell viability assay. For RNA extraction
and medium collection, 600 000 cells per well were plated on 6-well plates. After the cells
had attached, they were treated with 100 nM of FSH (#HOR-253, Immuno Diagnostics,
Hämeenlinna, Finland), 1000 nM of E2 (#E2758, Sigma-Aldrich, St Louis, MO, USA), 2 µM
testosterone (#86500, Sigma-Aldrich), or 5 µM dose of letrozole (#L6545, Sigma-Aldrich).
Cell viability was measured after 96 hours using the WST-1 assay (Sigma-Aldrich).
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Two-sided P value less than 0.05 was considered statistically significant. All data were
analyzed using JMP pro13.

2. Results
A. Primary and Recurrent AGCTs Show Distinct Transcriptional Profiles

B. AGCT Cells Express Highly Variable Levels of CYP19A1 Gene
To compare the gene expression levels of key hormone receptors in AGCTs to those in primary granulosa cells, we measured mRNA levels of FSHR, CYP19A1, ESR1, ESR2, and
GPER1 in hGL cells, an AGCT cell line KGN, and primary AGCT cells by qPCR analysis
(Fig. 1C-G). FSHR expression levels were higher in hGL cells compared with expression
in the KGN cell line and the expression levels of ESR2 were higher in both AGCT and
hGL cells compared with KGN cells (Fig. 1C, F). By contrast, the mRNA expression levels
for ESR1 were notably higher in hGL cells compared with KGN or primary AGCT cells
(Fig. 1E). Interestingly, CYP19A1 expression was minimal in hGL and KGN cells, whereas
the expression in AGCT cells varied widely among the individual samples (Fig. 1D), in line
with the result of the RNA-Seq analysis. The expression levels of GPER1 in AGCT cells
were similar to hGL and KGN cells (Fig. 1G).
C. FSHR Is Widely Expressed in AGCTs
Because gonadotropins are speculated to play a role in AGCT progression, we next
characterized the expression of FSHR in a larger cohort using RNA in situ hybridization
on a TMA of 175 AGCTs. FSHR mRNA was detected in 90% of AGCTs (Fig. 2A-D), and the
signal was strong or moderate in 60% of the tumors (Fig. 2A-D, Table 4). FSHR expression
was lower in tumors with high mitotic activity (P = 0.01), but expression did not correlate
with other clinical parameters such as tumor size, stage, or risk of recurrence.
D. Serum Inhibin B Levels Correlate Inversely With FSH Levels in AGCT Patients
Next, we analyzed FSH, E2, and inhibin B levels in 51 preoperative serum samples. FSH
levels were generally low in AGCT patients, with median levels of 1.55 IU/l (range 0.05–
15.3 IU/L) and 6.6 IU/L (range 0.1–60.3) in premenopausal and postmenopausal patients,
respectively. For E2 the median level was 0.125 nmol/L (range 0.01–0.48) in premenopausal
patients and 0.15 nmol/L (range 0.04–1.05) in postmenopausal patients. Serum FSH levels
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To characterize the expression levels of the hormonal pathway genes, we first performed
RNA sequencing of 6 primary and 4 recurrent AGCTs. Altogether, 1091 genes were differentially expressed between primary and recurrent tumors [40]. Six of these genes were involved in estrogen signaling, including 3 adenylate cyclase genes contributing to formation
of cAMP in response to G-protein signaling, and CREB3L1, encoding for cAMP-responsive
element, showing higher expression in primary tumors compared with recurrent tumors
(Fig. 1A). Among the genes with high expression in both primary and recurrent tumors
were heat shock protein 90B1 and members of the PI3K/Akt pathway. No significantly differentially expressed genes were found between relapsed and nonrelapsed primary tumors
after multiple testing correction [40]. However, when analyzing the hormonal pathway
genes (KEGG estrogen biosynthesis hsa04915) using unsupervised hierarchical clustering,
the primary and recurrent tumors clustered separately, indicating distinct transcriptional
profiles. Of the key hormonal regulators, FSHR was robustly expressed in all studied
samples (Fig. 1A-B). Interestingly, CYP19A1 expression was highly variable (range -0.07
to 9.85 Log2tpm) among the tumors. Of the estrogen receptors, ESR2 was the most highly
expressed (range 5.75–7.15 Log2tpm), whereas GPER1 expression levels were generally
low at the mRNA level (range 0.20–2.84 Log2tpm).
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were significantly lower in patients with large tumors (>10 cm in diameter) when compared
with patients with smaller tumors (<10 cm in diameter) (P = 0.001). FSH and E2 levels
did not correlate with each other; however, FSH and inhibin B levels showed a strong inverse correlation (Spearman rho -0.75, P < 0.0001), consistent with the suppressive effect
of circulating inhibin B on FSH secretion from the pituitary. In accordance with previous
findings [41], inhibin B levels were higher in patients with larger tumors (P = 0.01). Next,
we assessed the preoperative serum FSH levels from synchronous samples of 36 AGCT
patients whose tumors were represented in the TMA. We observed significantly increased
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Figure 1. Transcriptional profiling of 6 primary and 5 recurrent AGCTs using nextgeneration mRNA sequencing. (A) Heatmap showing the expression levels of differentially
expressed estrogen signaling genes between primary and recurrent samples (upper). Genes
with statistically significant differential expression (P < 0.05, false discovery rate < 0.25) are
marked with an asterisk. Lower part of the heatmap presents scaled expression levels of key
hormonal signaling genes in primary and recurrent AGCTs. (B) Violin plots showing the expression levels of key hormone receptors and CYP19A1 enzyme in the primary and recurrent
samples. (C-G) qPCR analysis showing the expression levels of key hormone receptors FSHR,
ESR1, ESR2, GPER1, and CYP19A1 enzyme in human granulosa lutel (hGL) cells, KGN cell
line and AGCT primary cells. All studied tumors were tested positive for FOXL2 mutation
and derived from postmenopausal patients. The data are shown as boxplots, where dots
represent individual samples, the box represents the interquartile range, and the whiskers
represent the first and fourth quartile. In comparisons between the groups, the asterisks indicate significant statistical difference (P < 0.05).
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Figure 2. FSHR mRNA expression and the effect of FSH stimulation in AGCTs. RNA
in situ hybridization was used to quantify FSHR expression in the AGCT TMA.
Representative images of (A,B) low and (C,D) high staining patterns. Original magnifications
80 × (scale bar: 20 µm) and 160 × (scale bar: 10 µm). Expression of (E) FSHR, (F) CYP19A1,
(G) ESR1, (H) ESR2, and (I) GPER1 was quantified in KGN cell line and cultured primary AGCT cells by qPCR after stimulation with FSH (0 or 100 ng/mL) for 96 hours. Black
columns: KGN cell line; gray columns: primary AGCT cells. (J) KGN data represents the
average of 3 independent experiments. Results are shown as mean ± SEM and statistical significance (P < 0.05) was assessed by 1-way ANOVA followed by Dunnett test.
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Table 4. Marker Distributions in AGCT Tissue Microarray
A
Marker

Negative n (%)

Weak n (%)

FSHR
(n = 165)
Cyp19A1
(n = 167)
GPER
(n = 161)

High n (%)

Primary

Recurrent

Primary

Recurrent

Primary

Recurrent

82 (71)

31 (62)

11 (10)

8 (16)

22 (19)

11 (22)

0

0

7 (6)

2 (5)

34 (31)

6 (14)

29 (27)

11 (25)

38 (35)

25 (57)

60 (54)

21 (48)

36 (32)

13 (30)

12 (11)

5 (11)

4 (4)

5 (11)

B
Marker

Intermediate n (%)

Primary Recurrent

RNA in situ hybridization
Negative n (%)

Weak n (%)

Intermediate n(%)

High n (%)

Primary

Recurrent

Primary

Recurrent

Primary

Recurrent

Primary Recurrent

11 (9)

6 (13)

31 (26)

18 (38)

60 (51)

21 (44)

15 (13)

3 (6)

104 (89)

38 (76)

8 (7)

5 (10)

5 (4)

7 (14)

0

0

106 (95)

33 (66)

5 (5)

17 (34)

0

0

0

0

tumor ERα expression in patients with low serum inhibin B levels (P = 0.04), suggesting diminished inhibin B–FSH feedback in high ERα expressing AGCTs. We found no significant
correlations between serum FSH or E2 levels and other estrogen receptors.
E. FSH Increases CYP19A1 Expression and E2 Production in AGCT Cells In Vitro
To study the functional role of FSH in AGCTs, KGN and primary AGCT cells were stimulated
with FSH for 96 hours and then gene expression levels and E2 production were measured by
qPCR and mass spectrometry, respectively. In KGN cells, FSHR expression was increased
by FSH stimulation (Fig. 2E). Also, CYP19A1 mRNA levels (Fig. 2F) and the amount of E2
in cell culture supernatants (Fig. 3A) were significantly increased by FSH. Additionally,
FSH stimulated the expression of ESR1, the gene encoding ERα, whereas no statistically
significant change in ERβ coding ESR2 or GPER1 levels was seen in KGN cells (Fig. 2G-I).
FSH stimulation did not have an effect on viability in this cell line (Fig. 2J).
In primary patient-derived AGCT cells, consistent with our findings in KGN cells, FSH
stimulation significantly increased the expression of CYP19A1 (Fig. 2F) and secretion of E2
into the culture medium (Fig. 3B). Interestingly, the level of FSH or E2 in patient´s preoperative serum sample did not correlate with the amount of E2 measured in the culture media
(Table 3). In contrast to the KGN cell line, FSH stimulation increased the mRNA expression of all the estrogen receptors (ESR1, ESR2, and GPER1) in all 6 of the patient-derived
primary AGCT cells (Fig. 2G-I). Moreover, FSH stimulation increased cell viability in 3 of
6 AGCT primary cell cultures by 26% to 43% (Fig. 2J, Table 3). Importantly, these results
indicate active hormonal signaling in AGCT cells.
F. CYP19A1 Is Expressed in a Subset of AGCTs
Aromatase inhibitors have been used in the treatment of relapsed AGCT [3]. These drugs
inhibit the synthesis of estrogens from androgen precursors by binding to aromatase. To
reveal the expression of CYP19A1 in a larger sample set, we performed RNA in situ hybridization and IHC on the TMA. CYP19A1 mRNA was detected in 15% of the tumor specimens
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Figure 3. Letrozole blocks E2 production but does not affect cell viability in primary AGCT
cells. KGN cells and 6 primary AGCT cultures were stimulated with FSH and letrozole (L)
for 96 hours. Testosterone (T) was provided as a substrate. (A-B) E2 concentrations in cell culture supernatants were measured by mass spectrometry. (C-D) After stimulation cell viability
was assessed by WST-1 assay. P values for (C) and (D) are shown in Table 5.

by RNA in situ hybridization (Fig. 4A-D). CYP19A1 immunoreactivity was detected in 48%
of the tumors, and 17% showed moderate or strong staining (Fig. 4E-H, Table 4). CYP19A1
mRNA expression correlated significantly with the moderate/high CYP19A1 protein expression (P < 0.0001). CYP19A1 protein expression also correlated positively with ERα expression (P = 0.009). There were no correlations between CYP19A1 expression and clinical
parameters such as tumor size, stage, or recurrence rate. Also, CYP19A1 expression in the
tumor tissue did not correlate with circulating E2, FSH, or inhibin B levels.
G. Aromatase Inhibition With Letrozole Suppresses E2 Production in AGCT Cells
Next, we studied the functional effects of CYP19A1 inhibition in KGN and primary AGCT cells.
For this purpose, cells were treated with a 5-µM dose of the aromatase inhibitor letrozole and
a 2-μM dose of testosterone as a substrate for CYP19A1. Testosterone significantly stimulated
both E2 production and cell viability in both KGN and primary AGCT cells, confirming the
presence of functional CYP19A1. FSH consistently enhanced the production of E2 in the presence of testosterone (Fig. 3A-B). Interestingly, letrozole treatment completely suppressed E2
production in the cell cultures (with and without FSH stimulation), but had no effect on cell
viability in either KGN or primary AGCT cells (Fig. 3C-D, P values shown in Table 5).
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H. ERβ Is the Main Estrogen Receptor in AGCTs and Its Expression Is Higher in
Recurrent Tumors
The expressions for estrogen receptors were further studied in the AGCT TMA using IHC
or RNA in situ hybridization. ERα immunoreactivity was observed in 33% of the tumors,
and ERβ protein was detected in 94% (Fig. 5A-H, Table 4). In the ERα-positive tumors,
the staining pattern was nuclear in 59% and cytoplasmic in 48% of the tumors. ERβ
immunoreactivity was exclusively nuclear and classified as moderate or strong in 67% of
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Figure 4. CYP19A1 is expressed in a subset of AGCTs. CYP19A1 expression was assessed in
the TMA by (A-D) RNA in situ hybridization and (E-H) IHC. Representative images of (A-B,
E-F) low and (C-D, G-H) high staining of AGCTs. Magnifications: (A-D) 80× (scale bar: 20 µm)
and (E-H) 160× (scale bar: 10 µm) and 50× (scale bar: 50 µm) and 100× (scale bar: 20 µm).
Arrows indicate positively stained cells.
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Table 5. P Values of the Hormone Stimulations (in Fig. 3) Using Student t-Test
A

Control

Testosterone

FSH

Testosterone
+ FSH

Testosterone
FSH
Testosterone + FSH
Testosterone + FSH
+ Letrozole

0.0001
<0.0001
0.506
0.897

<0.0001
<0.0001
<0.0001

0.061
0.021

0.591

B
pAGCT

Control

Testosterone

FSH

Testosterone
+ FSH

Testosterone
FSH
Testosterone + FSH
Testosterone + FSH
+ Letrozole

<0.0001
0.0002
<0.0001
<0.0001

0.473
0.771
0.447

0.667
0.146

0.297

the tumors. GPER1 mRNA expression was detected only in 14% of the tumors by RNA in
situ hybridization (Fig. 5I-L). Our results are in line with the data from mRNA sequencing
and thus confirm that ERβ is the predominant estrogen receptor in AGCT.
ERβ expression levels were significantly higher in recurrent AGCTs when compared
to primary tumors (P = 0.001). Furthermore, paired analysis of primary and recurrent
samples from same patients demonstrated a significantly stronger ERβ immunoreactivity
in the recurrent AGCTs (P = 0.0013) compared with the primary tumor (Fig. 6A). A similar
pattern between primary and recurrent samples was noted for GPER1 mRNA expression,
although the levels of expression were low (Fig. 6B). There were no significant differences
in the expression levels of ERα between primary and recurrent samples. We also found no
correlation between any of the estrogen receptor expression patterns and tumor size, stage
at primary diagnosis, recurrence rate, or menopause status at the time of sample retrieval.
None of the estrogen receptors had prognostic significance in terms of disease-free or overall
survival.
I. E2 Increases AGCT Cell Viability Only at High Concentrations
Because FSH stimulation increased aromatase expression, E2 production, and AGCT cell
viability, we next explored whether E2 alone affects AGCT cell viability. We found that exogenous E2 (0.1-1000 nM) did not affect the viability of KGN cells (Fig. 5P). Also, in primary
AGCT cells E2 did not increase the cell number at 0.1 to 100 nM concentrations. However,
the supraphysiological dose (1000 nM) increased the cell number on average by 36% in 4 of
the 6 studied samples (range 23%–57%) (Fig. 5P, Table 3). This 1000-nM dose reflects the
E2 concentrations that were seen in the AGCT cell culture supernatants after stimulation
with FSH, indicating that high local E2 concentrations may exist in AGCTs. In 1 recurrent
tumor, high E2 had no effect and in 1 primary tumor E2 decreased cell number by 21%.
Interestingly, the tumors that did not respond to high E2 also did not respond to FSH stimulation, suggesting heterogeneous hormonal dependencies in individual AGCTs. No correlation between the level of FSH or E2 in patient´s preoperative serum sample and response to
E2 stimulation could be seen (Table 3). We also found that E2 had no effect on the expression
levels of estrogen receptors ESR1, ESR2, and GPER1 in KGN cells (Fig. 5M-O). However, in
primary AGCT cells, E2 treatment increased ESR2 expression in all of the cultures indicating
a positive feedback mechanism of E2 and ESR2 expression in AGCTs (Fig. 5N).
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Figure 5. Expression of estrogen receptors and effects of E2 stimulation in AGCTs (A-H).
Expression of ERα and ERβ was assessed by IHC. Representative images of low and high
staining patterns, magnifications 50× (scale bar: 50 µm) and 100× (scale bar: 20 µm). (I-L)
Expression of GPER1 mRNA was determined by RNA in situ hybridization. Representative
images of low and high staining patterns, magnifications 80× (scale bars: 20 µm) and
160× (scale bars: 10 µm). (M-O) Expression of ESR1, ESR2, and GPER1 was assessed by
qPCR after stimulation with E2 (0-1000 nM) for 96 hours. (P) Cell viability was measured
after stimulation with E2 (0-1000 nM) for 96 hours. Black columns: KGN cell line; gray columns: primary AGCT cells.

3. Discussion
Hormonal activity is one of the hallmarks of AGCTs. Indeed, these tumors are often
diagnosed in perimenopause because of signs or symptoms of hormone production, such
as vaginal bleeding caused by estrogen-induced endometrial hyperplasia. As the peak incidence of AGCTs is in perimenopause or early postmenopause, it has been suggested that
alterations in circulating hormone levels, such as the rise in serum gonadotropin levels,
contributes to tumor formation. Additional knowledge on the possible hormonal modulation
of these unique tumors is needed given that anti-hormone therapies are currently used in
AGCT patient care.
Here, we first characterized the expression of sex hormone receptors at transcriptional
level using a large set of diagnostically validated AGCTs with an extensive clinical data and
follow-up time. In the transcriptional profiling, we did not find any significant differences in
the expression of hormone receptors between primary and recurrent tumors. Even though
our sample size in this experiment was limited, it supports earlier findings, as a previous
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transcriptomic analysis reported mainly similar expression patterns between stage I and
advanced AGCTs [42].
Genes with differential expression between primary and recurrent tumors included 3
adenylate cyclases, of which ADCY4 expression has earlier been correlated with better survival in breast cancer patients and ADCY3 has been recognized as a potential biomarker in
gastric cancer [43, 44]. A lower expression level for gene encoding for transcription factor
CREB3L1 in recurrent tumors was intriguing as decreased CREB3L1 expression has earlier
been linked to reduced progression free survival in breast cancer [45]. The high expression
levels of HSP90B1 in both primary and recurrent tumors were noteworthy as HSP90 chaperone proteins have been shown to regulate hormone receptors and have a crucial role in
normal granulosa cell function [46, 47]. According to an earlier report, increased HSP90B1
expression levels have been positively associated with ovarian granulosa cell proliferation
and survival [48]. The herein detected high expression levels of HSP90B1 and members of
the PI3K/Akt pathway suggest their role as potential targets for therapy. This is further
supported by the results from our previous work in which we performed unbiased highthroughput drug screening on AGCT samples demonstrating that both HSP90 and PI3Kinhibitors reduced the cell viability of AGCT cells [49]. Regardless, that these drugs were
not selective toward AGCT cells in comparison with normal granulosa cells in the screen,
our present finding supports the therapeutic potential of HSP90 and PI3K-inhibitors in
AGCT patients.
Consistent with our findings at the transcriptional level, we confirmed a strong uniform
expression of FSHR in a large set of AGCTs by using RNA in situ hybridization, a finding
that has not been shown earlier in more than a few individual AGCTs because of the lack
of specific IHC-compatible antibodies. Importantly, we observed an increase in cell number
in 3/6 of the tested primary AGCT samples following FSH stimulation. This FSH effect in
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Figure 6. ERβ and GPER1 expression levels were increased in recurrent AGCTs compared
with primary tumors. Paired analysis of the expression of estrogen receptors (A) ERβ and (B)
GPER1 in 16 patients with matched primary and recurrent tumor samples in the TMA.
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primary AGCT cultures is most likely mediated by P13K/Akt and MAPK pathways [50].
Cell viability was not affected in the KGN cell line by FSH, which may be due to the low
FSHR expression status in these cells. Our data on the low serum FSH levels is in line
with earlier findings in AGCT patients [51, 52], and the inverse correlation between serum
FSH and inhibin B levels in this study supports the notion that tumor-derived inhibin B
regulates pituitary FSH secretion.
The role of FSH in inducing CYP19A1 activity in normal granulosa cells is well established [53]. Regardless of the FSH stimulation priming of the hGL cells, the average
CYP19A1 mRNA expression levels tended to be higher in AGCTs. Further, we found a significant increase in expression of CYP19A1 gene after FSH stimulation in both KGN and
primary AGCT cells, supporting the role of FSH in E2 production in tumor cells. An earlier
study using primary rat granulosa cells showed that FSH regulates CYP19A1 via GATA4
[54], a transcription factor known to be overexpressed in AGCTs [55]. Another study reported the direct regulation of aromatase by FOXL2 and proposed that the C134W mutation
increases this stimulatory effect [16]. Moreover, induction of aromatase activity has been
observed as a consequence of the interaction of FOXL2C134W with SMAD3, a transcription
factor widely expressed in AGCTs [56, 57]. We found that CYP19A1 gene expression was
highly variable among studied AGCT samples both at the transcriptomic and protein level.
Moreover, the protein expression was positive in 48% of the studied tumors, which is a lower
proportion than previously reported [58, 59]. This finding might explain the observed variation in the responsiveness to anti-estrogen therapies [3, 10]. Furthermore, CYP19A1 expression may be dependent on constitutive FSH stimulation, which is suppressed in AGCT
patients through the downregulation of FSH secretion from the pituitary by tumor-derived
inhibin B. Another factor secreted by AGCTs, anti-Müllerian hormone, has been shown
to attenuate FSH-mediated stimulation of CYP19A1 expression [13]. Thus, the observed
variability between individual AGCTs may be due to the complex regulatory networks of
CYP19A1 expression [60].
The role of E2 in AGCT growth and survival has been controversial. Estrogen promotes
tumor growth in various cancers [61], and the safety of estrogen replacement therapy of
AGCT patients remains questionable [62]. In a previous study with a long follow-up time,
postmenopausal estrogen replacement therapy did not negatively impact the prognosis of
AGCT patients [63]. Furthermore, earlier studies on KGN cells did not support a growthstimulating effect of E2 [21, 22, 64]; indeed, it has been shown that E2 may decrease KGN
cell migration [22]. In line with these reports, we did not find any effect on KGN cell viability
in response to E2 stimulation. Further, in the primary AGCT cell cultures, no effects on cell
viability were seen at physiological concentrations. However, an increase in cell number
was detected in 4/6 of the primary AGCT cell cultures tested when using an extremely high
estradiol dose. Our results thus confirm the earlier findings of negligible responsiveness of
AGCTs cells to estradiol and provide further evidence on that estrogen replacement therapy
can be considered safe in AGCT patients with no evidence of disease.
Consistent with earlier studies [7, 20], we found that ERβ was the principal estrogen
receptor expressed in AGCTs. ERα expression was markedly lower than ERβ, but its correlation with circulating FSH and tissue CYP19A1 expression and that FSH stimulation
increased ERα expression suggest that ERα may have a functional role in a subset of
AGCTs. In other hormone-related malignancies, such as breast and prostate cancer, ERα is
considered tumorigenic, whereas ERβ mostly functions as a tumor suppressor by blocking
the proliferation and inducing apoptosis [61, 65, 66]. ERβ effects are also dependent on the
ERβ-subtype [67, 68]. Increased ERβ expression in recurrent tumors suggests the significance of ERβ in this unique slow growing tumor type, but the specific effect of ERβ in tumor
progression awaits further evidence. It is of note that GPER1 expression was shown to be
minimal both according to the RNA sequencing and RNA in situ methods, contradicting
earlier findings reporting its expression in AGCT [22]. We observed robust RNA expression of FSHR and ESR1 in hGL cells consistent with the FSH-priming associated with
the IVF protocol. Consistent with previous observations, we confirmed strong expression
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